Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.950
+0.190 (6.88%)
At close: Mar 13, 2026, 4:00 PM EDT
2.920
-0.030 (-1.02%)
After-hours: Mar 13, 2026, 6:46 PM EDT
Processa Pharmaceuticals Employees
Processa Pharmaceuticals had 10 employees as of December 31, 2024. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
n/a
Profits / Employee
-$1,293,360
Market Cap
6.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 10 | -3 | -23.08% |
| Dec 31, 2023 | 13 | -2 | -13.33% |
| Dec 31, 2022 | 15 | 0 | - |
| Dec 31, 2021 | 15 | 1 | 7.14% |
| Dec 31, 2020 | 14 | 1 | 7.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| Moleculin Biotech | 17 |
| Dogwood Therapeutics | 12 |
| Immuron | 7 |
| Mustang Bio | 6 |
| Xenetic Biosciences | 2 |
| PharmaCyte Biotech | 2 |
| SciSparc | 2 |
PCSA News
- 2 months ago - Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study - GlobeNewsWire
- 3 months ago - Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data? - Benzinga
- 3 months ago - Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer - GlobeNewsWire
- 4 months ago - Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 - GlobeNewsWire
- 7 months ago - Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies - GlobeNewsWire
- 9 months ago - Processa Pharmaceuticals Provides Portfolio and Business Update - GlobeNewsWire
- 9 months ago - Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewsWire